Research prototype, not medical advice.

11 — Chronic inflammation (chronic inflammation, "inflammaging")

"Integrative" hallmark added explicitly in the update by López-Otín et al., Cell 2023 (10.1016/j.cell.2022.11.001). It brings together age-related low-grade inflammation, immunosenescence and clonal hematopoiesis.

1. Definition

With age, the body maintains a weak but permanent inflammation, with no apparent infection or injury. Franceschi named it inflammaging (inflammation + aging) (Franceschi 2000, 10.1111/j.1749-6632.2000.tb06651.x). At the same time, the immune system becomes less effective against real threats (immunosenescence).

In plain terms: the body's fire alarm keeps ringing softly all the time. It wears out the tissues, but when a real fire (infection, cancer) breaks out, the firefighters are tired and respond badly.

2. Mechanisms and sources

3. Symptoms and clinical manifestations

Chronic inflammation is a risk factor shared by most age-related diseases (Furman 2019, 10.1038/s41591-019-0675-0):

Measurement in humans: high-sensitivity CRP, IL-6 and TNF-α are associated with mortality and multimorbidity in older people. An "inflammatory clock" (iAge), built by deep learning on blood cytokines, tracks multimorbidity, immunosenescence and frailty (Sayed 2021, 10.1038/s43587-021-00082-y).

4. Interactions with the other hallmarks

5. Existing or investigational remedies

InterventionTargetLevel of evidenceKey resultSource
Canakinumab (anti-IL-1β), CANTOS trialIL-1βHuman phase III trial−15% cardiovascular events in post-heart-attack patients with high CRP; more fatal infectionsRidker 2017
Low-dose colchicine, COLCOTPost-heart-attack inflammationHuman phase III trialFewer ischemic events after heart attackTardif 2019
Low-dose colchicine, LoDoCo2Chronic coronary diseaseHuman phase III trial; approved (FDA 2023) for cardiovascular preventionFewer cardiovascular eventsNidorf 2020
NLRP3 inhibition (genetic)InflammasomePreclinical (mice)Less inflammation and functional declineYoum 2013
STING inhibitioncGAS-STING pathwayPreclinical (mice)Less inflammation, better cognitive and physical functionGulen 2023
Blocking the PGE2 receptor EP2Old macrophagesPreclinical (mice)Cognitive decline reversedMinhas 2021
Moderate caloric restriction (CALERIE)Systemic inflammationRandomised human trial (2 years)Lower inflammatory markers without impairing immunityMeydani 2016
mTORC1 inhibitors (rapalogs)ImmunosenescenceHuman phase IIa trialBetter vaccine response, fewer infections in older peopleMannick 2018
Senolytics (dasatinib + quercetin)Senescent cells / SASPOpen-label human pilot trial (pulmonary fibrosis, n=14)Improved physical function, feasibleJustice 2019
Metformin (TAME project)Metabolism, inflammationProposed human trial (TAME, no results yet)Rationale for targeting aging itselfBarzilai 2016

Key point: CANTOS is the proof in humans that reducing inflammation alone reduces age-related diseases. But the price is a higher risk of infection: the target must be chosen carefully.

6. Open questions

7. References